08 mayo 2018
Pharma Mar : Sylentis announces new data on the treatment of allergic conjunctivitis .
Within the framework of ARVO 2018,
Sylentis announces new data on the treatment of allergic conjunctivitis
The results of SYL116011 have demonstrated that this treatment reduces the symptoms related to the allergy in 50% to 80%i.
The ARVO meeting has considered the poster presentation to be of scientific interest, contributing therefore to its release.
Around 30% of the worldwide population show allergic symptoms and between 40-80% of them have the symptoms in their eyesii.
Entrada más reciente